Int. J. Mol. Sci. 2012, 13(10), 12925-12938; doi:10.3390/ijms131012925
Review

Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure

1email, 1,2,3email, 1,* email and 3,4,* email
Received: 3 August 2012; in revised form: 19 September 2012 / Accepted: 29 September 2012 / Published: 10 October 2012
(This article belongs to the Special Issue Cancer Molecules in Ovarian Cancer 2012)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The present study investigated the expression and clinical role of hyaluronan synthases (HAS1-3) and hyaluronidases (Hyal1-3) in serous ovarian carcinoma. HAS and HYAL mRNA expression was analyzed in 97 tumors (61 effusions, 27 primary carcinomas, 9 solid metastases) using PCR and further studied for association with clinicopathologic parameters, including survival. HAS1 mRNA was overexpressed in effusions compared to primary carcinomas and solid metastases (p < 0.001), and an alternatively spliced HAS1 was expressed only in effusions. HAS2 mRNA was overexpressed in solid metastases and primary carcinomas compared to effusions (p = 0.043), and HAS3 mRNA was overexpressed in primary carcinomas and effusions compared to solid metastases (p = 0.008). HYAL1 mRNA was absent in all specimens, whereas HYAL2 was expressed as two splice variants, of which HYAL2-var2 was overexpressed in solid metastases compared to effusions and primary carcinomas (p < 0.001). HYAL3 mRNA was expressed as wild-type and variant 1-3 form, the latter more highly in primary carcinomas and effusions compared to solid metastases (p = 0.006). HAS1 mRNA was overexpressed in pre- compared to post-chemotherapy effusions (p < 0.001), with opposite finding for HYAL2-var1 and HYAL3-WT (p = 0.016 and p = 0.024, respectively). Higher HYAL2-var1 and HAS1 splice variant mRNA expression in effusions was associated with longer (p = 0.033) and shorter (p = 0.047) overall survival, respectively. These data are the first to document a role for HAS and Hyal members in tumor progression in ovarian carcinoma, as evidenced by their differential expression as function of anatomic site and chemotherapy exposure, with a possible prognostic role for patients with malignant effusions.
Keywords: hyaluronan synthase; hyaluronidase; ovarian carcinoma; tumor progression; effusions; survival
PDF Full-text Download PDF Full-Text [394 KB, uploaded 19 June 2014 04:28 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Weiss, I.; Trope, C.G.; Reich, R.; Davidson, B. Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure. Int. J. Mol. Sci. 2012, 13, 12925-12938.

AMA Style

Weiss I, Trope CG, Reich R, Davidson B. Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure. International Journal of Molecular Sciences. 2012; 13(10):12925-12938.

Chicago/Turabian Style

Weiss, Ilana; Trope, Claes G.; Reich, Reuven; Davidson, Ben. 2012. "Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure." Int. J. Mol. Sci. 13, no. 10: 12925-12938.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert